Taysha Gene Therapies Inc (TSHA)
3.09
-0.05
(-1.59%)
USD |
NASDAQ |
May 17, 16:00
3.08
-0.01
(-0.32%)
After-Hours: 20:00
Taysha Gene Therapies Enterprise Value: 494.42M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 494.42M |
| May 16, 2024 | 503.77M |
| May 15, 2024 | 498.16M |
| May 14, 2024 | 397.17M |
| May 13, 2024 | 365.38M |
| May 10, 2024 | 354.15M |
| May 09, 2024 | 389.69M |
| May 08, 2024 | 361.64M |
| May 07, 2024 | 380.34M |
| May 06, 2024 | 406.52M |
| May 03, 2024 | 397.17M |
| May 02, 2024 | 399.04M |
| May 01, 2024 | 369.12M |
| April 30, 2024 | 370.99M |
| April 29, 2024 | 374.73M |
| April 26, 2024 | 363.51M |
| April 25, 2024 | 346.67M |
| April 24, 2024 | 356.02M |
| April 23, 2024 | 389.69M |
| April 22, 2024 | 376.60M |
| April 19, 2024 | 341.06M |
| April 18, 2024 | 367.25M |
| April 17, 2024 | 374.73M |
| April 16, 2024 | 398.10M |
| April 15, 2024 | 414.00M |
| Date | Value |
|---|---|
| April 12, 2024 | 466.37M |
| April 11, 2024 | 518.73M |
| April 10, 2024 | 503.77M |
| April 09, 2024 | 470.11M |
| April 08, 2024 | 417.74M |
| April 05, 2024 | 417.74M |
| April 04, 2024 | 417.74M |
| April 03, 2024 | 425.22M |
| April 02, 2024 | 423.35M |
| April 01, 2024 | 447.66M |
| March 31, 2024 | 453.27M |
| March 28, 2024 | 433.31M |
| March 27, 2024 | 489.42M |
| March 26, 2024 | 468.84M |
| March 25, 2024 | 468.84M |
| March 22, 2024 | 504.38M |
| March 21, 2024 | 476.32M |
| March 20, 2024 | 450.14M |
| March 19, 2024 | 317.36M |
| March 18, 2024 | 294.79M |
| March 15, 2024 | 326.58M |
| March 14, 2024 | 296.66M |
| March 13, 2024 | 319.10M |
| March 12, 2024 | 317.23M |
| March 11, 2024 | 334.05M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-8.649M
Minimum
Mar 29 2023
947.67M
Maximum
Jan 20 2021
314.24M
Average
229.36M
Median
Jan 05 2024
Enterprise Value Benchmarks
| Aquestive Therapeutics Inc | 216.71M |
| Lifecore Biomedical Inc | -- |
| Relmada Therapeutics Inc | 17.17M |
| ACADIA Pharmaceuticals Inc | 1.973B |
| Cyclacel Pharmaceuticals Inc | -0.3591M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.06M |
| Revenue (Quarterly) | 3.411M |
| Total Expenses (Quarterly) | 27.74M |
| EPS Diluted (Quarterly) | -0.10 |
| Profit Margin (Quarterly) | -705.4% |
| Earnings Yield | -37.37% |
| Normalized Earnings Yield | -20.04 |